...
首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
【24h】

ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

机译:ARID1A是促进SWI / SNF介导的染色质重塑形成的因子,是妇科癌症中的肿瘤抑制因子。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

ARID1A (BAF250A) promotes the formation of SWI/SNF chromatin remodeling complexes containing BRG1 or BRM. It has emerged as a candidate tumor suppressor based on its frequent mutations in ovarian clear cell and endometrioid cancers and in uterine endometrioid carcinomas. Here, we report that restoring wild-type ARID1A expression in ovarian cancer cells that harbor ARID1A mutations is sufficient to suppress cell proliferation and tumor growth in mice, whereas RNA interference-mediated silencing of ARID1A in nontransformed epithelial cells is sufficient to enhance cellular proliferation and tumorigenicity. Gene expression analysis identified several downstream targets of ARID1A including CDKN1A and SMAD3, which are well-known p53 target genes. In support of the likelihood that p53 mediates the effects of ARID1A on these genes, we showed that p53 was required and sufficient for their regulation by ARID1A. Furthermore, we showed that CDKN1A (encoding p21) acted in part to mediate growth suppression by ARID1A. Finally, we obtained evidence that the ARID1A/BRG1 complex interacted directly with p53 and that mutations in the ARID1A and TP53 genes were mutually exclusive in tumor specimens examined. Our results provide functional evidence in support of the hypothesis that ARID1A is a bona fide tumor suppressor that collaborates with p53 to regulate CDKN1A and SMAD3 transcription and tumor growth in gynecologic cancers.
机译:ARID1A(BAF250A)促进含有BRG1或BRM的SWI / SNF染色质重塑复合物的形成。基于其在卵巢透明细胞和子宫内膜样癌以及子宫内膜样癌中的频繁突变,它已成为候选的肿瘤抑制物。在这里,我们报告说,在具有ARID1A突变的卵巢癌细胞中恢复野生型ARID1A表达足以抑制小鼠中的细胞增殖和肿瘤生长,而RNA干扰介导的ARID1A在未转化的上皮细胞中的沉默足以增强细胞增殖和致瘤性。基因表达分析确定了ARID1A的多个下游靶标,包括CDKN1A和SMAD3,它们是众所周知的p53靶标基因。为了证明p53介导ARID1A对这些基因的作用的可能性,我们证明了p53是必需的,并且足以由ARID1A对其进行调节。此外,我们显示CDKN1A(编码p21)在部分程度上通过ARID1A介导生长抑制。最后,我们获得了证据,表明ARID1A / BRG1复合物直接与p53相互作用,并且ARID1A和TP53基因的突变在所检查的肿瘤标本中互斥。我们的结果提供了功能性证​​据,以支持ARID1A是一种真正的肿瘤抑制因子,与p53协同调节妇科癌症中的CDKN1A和SMAD3转录以及肿瘤生长这一假说。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号